GCS-100 selectively kills KRAS-addicted lung tumors.

Slides:

Advertisements

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Advertisements

Volume 24, Issue 5, Pages (November 2013)

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Binding of 53BP1 on uncapped telomeres.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Effects of SC144 on in vivo ovarian tumor.

BV6 increases tumor burden in bone.

Validation of St6GalNAc2 as a metastasis suppressor gene.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Deficiency of Cdkn2a leads to aberrant activation of RhoA in vivo.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Volume 25, Issue 13, Pages e2 (December 2018)

KRAS-induced chemoattractants mediate attraction of macrophages.

Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+ tumors Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+

Sequencing and PDX technologies for the identification and validation of therapeutic targets in non–V600 mutant BRAF melanoma. Sequencing and PDX technologies.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Volume 19, Issue 6, Pages (June 2011)

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in vitro and in vivo. Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded skin. PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Histopathology of anal tissue.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

AMs contribute to the progression of EGFR-mutant lung adenocarcinoma.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid cells. Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid.

Presence of TNF and ECM degradation are consequences of abundance of macrophages in regions of ADM. A, pancreata of p48Cre;LSL-KrasG12D treated with PBS.

SY-1425 induces maturation in RARA-high AML

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

B. fragilis utilizes TLR2 signaling for its protective role against the development of colitis-associated cancer in mice. B. fragilis utilizes TLR2 signaling.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

In vivo effects of TTFields on intradermal tumors in mice.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

BMX is a driver of castration resistance in vitro and in vivo.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Effects of ZOL treatment on pulmonary metastases.

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS levels. KRAS-addicted lung cancer cells need αvβ3/galectin-3 to maintain low ROS.

VEGF-A inhibition impedes proliferation in Amppos tumors.

Greater influx of PMNs and ST using PEGPH20/shIDO-ST.

PEGPH20 depletes HA and decompresses intratumoral vessels.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

SCLC in CMV TKO mice arises from an alternative cell of origin.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

GCS-100 selectively kills KRAS-addicted lung tumors. GCS-100 selectively kills KRAS-addicted lung tumors. A, Mice with established subcutaneous KRAS-mutant lung PDX-8 tumors were treated with vehicle (n = 9) or GCS-100 (n = 10; 20 mg/kg i.p. 3 times per week) for 15 days. Change in tumor volume vs. time (left) and after 15 days of treatment (right). B, Sections from PDX-8 tumors were stained for TUNEL as an indicator of apoptosis, and the percent of TUNEL+ cells quantified using ImageJ. Scale bar, 50 μm. C, LSL-KrasG12D mice were infected with Adeno-Cre via intratracheal injection. After 3 months, sections of lung tissue reveal β3-expressing tumors with areas of adenoma, dysplasia, and adenocarcinoma. Scale bars, 50 μm. D and E, Mice were randomized and treated with either vehicle control or GCS-100 for 1 additional month. Representative histologic images show lung tumor burden. Scale bar, 2 mm, and 500 μm for inset. Tumor burden (tumor area as a percentage of total lung area) in LSL-KrasG12D mice treated with vehicle (n = 7) or GCS-100 (n = 7) at a dose of 20 mg/kg i.p. 3 times per week. Table shows effect of the drug on tumor histopathology. F, Effect of GCS-100 on apoptosis, evaluated using TUNEL staining by IHC. Scale bar, 50 μm. All data represent mean ± SD from at least three independent experiments. Statistical significance was determined by the Student t test. **, P < 0.01; ***, P < 0.001. Laetitia Seguin et al. Cancer Discov 2017;7:1464-1479 ©2017 by American Association for Cancer Research